The AstraZeneca Translational Medicine Oncology group routinely uses NGS panels for biomedical research and for profiling of retrospective clinical trials samples.  The latest internal assay, AZ700, covers the exonic regions of 697 genes, with content tailored to fit the broad needs of AstraZeneca's drug pipeline.  Greater than 1000X coverage is routinely achieved with Formalin Fixed Paraffin Embedded Tissue material.  This allows a limit of detection for Single Nucleotide Variants (SNVs) and small Insertions/Deletion (indels) below 1% VAF.  The AZ700 panel is being utilized to profile samples with the aim of identifying biomarkers of response and resistance.